Spots Global Cancer Trial Database for Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML
Official Title: A Phase II, Multi-center, Open Label, Randomized Study of Ribavirin and Hedgehog Inhibitor With or Without Decitabine in Acute Myeloid Leukemia (AML)
Study ID: NCT02073838
Conditions
Study Description
Brief Summary: This is a research study of ribavirin which will be given in combination with vismodegib and/or decitabine. The purpose of this study is to see if patients respond to treatment when ribavirin is given with vismodegib alone or in combination with decitabine.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Jewish General Hospital, Montreal, Quebec, Canada
Contact Details
Name: Sarit Assouline, MD
Affiliation: Jewish General Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
